....MNTA can use some of its cash horde to fund an M-Copax clinical trial.
From Dew's post -
This has been asked and answered on several occasions. The simple and direct answer is that the FDA accepted NVS/MNTA’s Copaxone application for review under the 505j (ANDA) regulatory pathway.
....the whole point of the 505j regulatory pathway is to allow generic drugs to come to market without clinical trials....
Market Data 
Markets 
AI
